Streetbeat News

Products Services

ASST

Asset Entities announced a demo of their MiQb AI platform, featuring a special Deadpool and Wolverine theme. The demo includes a limited number of scans for an exclusive T-shirt.

Portfolio Pulse from charles@benzinga.com

July 26, 2024 | 6:43 pm

GOOG

GOOGL

META

Needham analyst Laura Martin reiterated an Underperform rating for Meta Platforms Inc (NASDAQ:META) and compared the valuations and monetization of short-form video platforms TikTok, Instagram Reels, and YouTube Shorts. TikTok excels in revenue generation and engagement, Reels has the most monthly users, and Shorts has high user engagement. Reels is the most successful at driving sales, followed by Shorts and TikTok. Ad buyers appreciate TikTok's young demographics and interactive features but are wary of a potential U.S. government ban. Reels is praised for its wide demographic base and precise targeting, while Shorts benefits from integration with the YouTube ecosystem.

Portfolio Pulse from Hayden Buckfire

July 26, 2024 | 6:42 pm

EWA

FXI

INDA

SPY

U.S. Treasury Secretary Janet Yellen stated that the United Nations lacks the expertise to handle global tax issues and involves too many countries. She mentioned that significant progress has been made in the Pillar 1 talks on digital taxes, but India, China, and Australia are still holding out.

Portfolio Pulse from charles@benzinga.com

July 26, 2024 | 6:38 pm

TSLA

XPEV

XPeng Inc. (NYSE:XPEV) shares are trading higher after the company's Chairman & CEO announced plans to launch a 'highly competitive' Robotaxi in 2026. XPeng's approach will differ from Tesla's by not involving itself in operations but partnering with other companies. Additionally, XPeng plans to introduce a new model without LiDAR technology in the fourth quarter.

Portfolio Pulse from Nabaparna Bhattacharya

July 26, 2024 | 6:22 pm

TLRY

Tilray Brands, Inc. (NASDAQ:TLRY) shares are trending as the company is set to release its 2024 fiscal year and fourth quarter earnings on Monday. Analysts estimate a loss of 2 cents per share and revenue of $227.07 million. The stock is currently trading at $1.81, close to its 50-day moving average of $1.8 and on the lower end of its 52-week range of $1.6 to $3.4. Recently, Tilray received approval for a medical cannabis extract in Portugal and saw a 6.70% increase in stock price following President Biden's announcement that he is not seeking re-election.

Portfolio Pulse from Dylan Berman

July 26, 2024 | 6:21 pm

AQST

Aquestive Therapeutics shares are trading higher after the company released positive topline PK data from the self-administration study of Anaphylm, meeting primary endpoints. The final OAS challenge study is enrolling, and a pre-NDA meeting is expected by the end of Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 6:14 pm

IYT

NRSH

NSC

Norfolk Southern Corporation (NYSE:NSC) reported strong Q2 financial results, leading to several analysts revising their price targets. The company reported $3 billion in railway operating revenue and adjusted earnings of $3.06 per share, beating estimates. Analysts from RBC Capital Markets, Goldman Sachs, Stifel, and Wells Fargo have adjusted their price targets and ratings, reflecting confidence in NSC's long-term efficiency and productivity gains. Investors can also gain exposure through IShares U.S. Transportation ETF (BATS:IYT) and Tidal ETF Trust Aztlan North America Nearshoring Stock Selection ETF (NYSE:NRSH).

Portfolio Pulse from Lekha Gupta

July 26, 2024 | 6:10 pm

AMC

DIS

IMAX

Disney, AMC, and IMAX stocks surged after 'Deadpool & Wolverine' broke box office records with $38.5 million in Thursday previews, the highest ever for an R-rated film. The film's success is expected to continue over the weekend, boosting the prospects of Disney, AMC Entertainment, and IMAX.

Portfolio Pulse from Anusuya Lahiri

July 26, 2024 | 6:05 pm

FXI

Boeing has requested its suppliers to disclose all paperwork related to titanium purchased from China since 2014 by August 9. This move is likely in response to regulatory or quality concerns.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 6:05 pm

AZN

AstraZeneca's CEO Pascal Soriot has urged the UK government to review its drug pricing assessment after NICE deemed the company's breast cancer drug Enhertu too expensive. Enhertu, developed with Daiichi Sankyo, has shown significant results but may not be available for treating advanced breast cancer in England due to its high cost. Despite challenges, AstraZeneca reported robust sales growth, with Enhertu contributing significantly.

Portfolio Pulse from Vandana Singh

July 26, 2024 | 6:01 pm